Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Eli Lilly said sales of its blockbuster diabetes treatment, Trulicity, rose 20% from last year to $1.23 billion, but overall revenues missed analysts' forecasts. Eli Lilly & Co. (LLY) posted ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Eli Lilly’s revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a ...
Lilly also has other big winners in its lineup. Sales for cancer drug Verzenio jumped 40% year over year in Q1. Diabetes drug ...
Wall Street Insights Unlike the declining stocks of some of its pharmaceutical rivals, Eli Lilly has continually beat ...
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
CAPE CANAVERAL, Fla. — Boeing Co. is now aiming for its first astronaut launch at the beginning of June, after spending the past few weeks struggling with more problems on the space capsule.
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing sales ...